Thermo Fisher Scientific (TMO) Non-Current Debt (2009 - 2026)

Thermo Fisher Scientific has disclosed Non-Current Debt across 18 years of filings, most recently posting $40.1 billion for Q1 2026.

• Quarterly Non-Current Debt rose 27.74% year-over-year to $40.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.1 billion (up 27.74% YoY) and the FY2025 annual result came in at $35.9 billion, up 23.37% from the prior year.
• Non-Current Debt advanced to $40.1 billion in Q1 2026, from $35.9 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $40.1 billion in Q1 2026 and troughed at $28.2 billion in Q4 2022.
• A 5-year average of $31.3 billion and a median of $31.2 billion in 2024 frame the typical range for Non-Current Debt.
• Biggest YoY gain for Non-Current Debt was 68.39% in 2022; the steepest drop was 10.59% in 2022.
• Tracing TMO's Non-Current Debt over 5 years: stood at $28.9 billion in 2022, then gained by 8.3% to $31.3 billion in 2023, then fell by 7.18% to $29.1 billion in 2024, then advanced by 23.37% to $35.9 billion in 2025, then advanced by 11.77% to $40.1 billion in 2026.
• Business Quant data shows TMO's Non-Current Debt at $40.1 billion in Q1 2026, $35.9 billion in Q4 2025, and $31.9 billion in Q3 2025.